Tamarack Advisers’s Biogen BIIB Stock Holding History

Tamarack Advisers’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-20,000	Closed	-$5.54M	–	41
2022 Q4	$5.54M	Buy	+20,000	New	+$5.65M	2.85%	12

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tamarack Advisers's BIIB Position: Q1 2023 in Review

Tamarack Advisers sold out of Biogen (BIIB) in Q1 2023, closing a stake of 20,000 shares — an estimated $5.54M sold.

Tamarack Advisers first reported a position in BIIB in Q4 2022 and held it in 1 quarter. The position peaked at $5.54M in Q4 2022. 1,001 funds tracked by Wall St. Rank hold BIIB as of Q1 2023.

Tamarack Advisers reported no remaining Biogen position as of Q1 2023 after selling out during the quarter.
Tamarack Advisers sold 20,000 Biogen shares in Q1 2023, an estimated $5.54M.
Tamarack Advisers first reported a position in Biogen in Q4 2022 and held it in 1 quarter.
Tamarack Advisers's Biogen position peaked at $5.54M in Q4 2022.
1,001 funds tracked by Wall St. Rank held Biogen as of Q1 2023.

Based on Tamarack Advisers's 13F filing for Q1 2023, filed 11 May 2023.